Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nanoviricides Inc (NY: NNVC ) 1.760 +0.020 (+1.14%) Streaming Delayed Price Updated: 9:41 AM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nanoviricides Inc < Previous 1 2 3 4 5 6 Next > Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach February 28, 2022 Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... Via Benzinga 27 Stocks Moving in Monday's Pre-Market Session February 28, 2022 Gainers Mullen Automotive, Inc. (NASDAQ: MULN) rose 45.4% to $1.00 in pre-market trading after the company reported progress on solid-state polymer battery pack development.... Via Benzinga NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready February 15, 2022 SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... From NanoViricides, Inc. Via AccessWire Topics Regulatory Compliance Exposures COVID-19 Legal Regulatory How Many Boosters Will It Take? A Global Population Beset By Pandemic Fatigue Wants A More Permanent Solution January 31, 2022 Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts January 19, 2022 Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. As the threat... Via Benzinga NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market December 20, 2021 Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... Via Benzinga NanoViricides Says Its Nanomedicine Tech Could Be the Key To Defeating Omicron and Other COVID-19 Variants December 09, 2021 Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... Via Benzinga Exposures COVID-19 These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19 November 29, 2021 Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... Via Benzinga NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials November 16, 2021 SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... From NanoViricides, Inc. Via AccessWire Topics Regulatory Compliance Exposures COVID-19 Legal Product Safety EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment November 15, 2021 NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized... Via Benzinga Exposures COVID-19 Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday November 15, 2021 Welcome back, trader! We're getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday! Via InvestorPlace NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 November 15, 2021 SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel... From NanoViricides, Inc. Via AccessWire Exposures COVID-19 Product Safety EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate November 15, 2021 NanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What... Via Benzinga Exposures COVID-19 Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach November 05, 2021 Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... Via Benzinga Exposures COVID-19 Are Pfizer, Moderna, J&J Booster Shots a Panacea? This Company Says Its Broad-Spectrum Drugs to Fight COVID-19 Would Help End the Pandemic November 02, 2021 Photo by Steven Cornfield on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... Via Benzinga Exposures COVID-19 NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage October 13, 2021 SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021... From NanoViricides, Inc. Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal NanoViricides COVID-19 Treatment Candidate Found Effective Against Coronavirus Variants In Lab Study October 11, 2021 Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides... Via Benzinga Exposures COVID-19 Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market October 11, 2021 Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure... Via FinancialNewsMedia Exposures COVID-19 NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity October 11, 2021 Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral... Via Benzinga Exposures COVID-19 NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity October 11, 2021 SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel... From NanoViricides, Inc. Via AccessWire Exposures COVID-19 Product Safety NanoViricides Leaps Forward in its Quest to Defeat COVID-19 October 05, 2021 Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19.... Via Benzinga Exposures COVID-19 31 Stocks Moving In Monday's Mid-Day Session September 27, 2021 Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to... Via Benzinga 20 Stocks Moving in Monday's Pre-Market Session September 27, 2021 Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading. Paltalk, Inc. (NASDAQ: PALT) rose 43.9% to $5.77 in pre-market... Via Benzinga 50 Biggest Movers From Yesterday September 23, 2021 Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement from management that the company entered into a... Via Benzinga 32 Stocks Moving In Wednesday's Mid-Day Session September 22, 2021 Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share... Via Benzinga Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern September 21, 2021 Nanoviricides Inc. (NYSE:NNVC) shares are surging higher Tue... Via Benzinga What Is a ‘News Pending’ Halt? What to Know as NNVC Stock Captivates Investors September 21, 2021 Today, NanoViricides is grabbing a lot of attention due to a news pending halt that has sent NNVC stock skyrocketing. Via InvestorPlace EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile September 21, 2021 NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-... Via Benzinga Exposures COVID-19 53 Biggest Movers From Yesterday September 16, 2021 Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... Via Benzinga Topics Initial Public Offering Exposures Securities Market 38 Stocks Moving In Wednesday's Mid-Day Session September 15, 2021 Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of... Via Benzinga Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
